Literature DB >> 28663026

Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis.

Miquel Bioque1, M A Paz García-Portilla2, Clemente García-Rizo3, Bibiana Cabrera4, Antonio Lobo5, Ana González-Pinto6, Covadonga M Díaz-Caneja7, Iluminada Corripio8, Eduard Vieta9, Josefina Castro-Fornieles10, Julio Bobes11, Miguel Gutiérrez-Fraile12, Roberto Rodriguez-Jimenez13, Gisela Mezquida4, Adrián Llerena14, Jeronimo Saiz-Ruiz15, Miguel Bernardo16.   

Abstract

Patients with a first episode of psychosis (FEP) display a broad range of metabolic risk factors related to the development of diverse medical comorbidities. Initial stages of these disorders are essential in understanding the increased vulnerability of developing cardiometabolic disturbances, associated with a reduced life expectancy. This study aimed to evaluate the metabolic profile of a cohort of patients with a FEP and its evolution during a two year follow-up, as well as the factors that influence the changes in their metabolic status. 16 participating centers from the PEPs Project recruited 335 subjects with a FEP and 253 matched healthy controls, aged 9-35years. We investigated a set of anthropometric measures, vital signs and laboratory data obtained from each participant over two years in a prospective, naturalistic study. From the beginning of the study the FEP group showed differences in the metabolic profile compared to the control group, together with a progressive worsening in the major part of the analyzed variables during the follow-up period, with higher rates of obesity and metabolic syndrome. Certain risk factors were related to determinate clinical variables such as male gender, the presence of affective symptoms or an early onset or to treatment variables such as the use of antipsychotic polypharmacy, antidepressants or mood stabilizers. Our results highlight the extremely high risk of patients at early phases of schizophrenia and other psychotic disorders of developing cardiovascular comorbidity and the fast worsening of the metabolic profile during the first two years.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antipsychotics; Diabetes; Metabolic syndrome; Metabolism; Psycosis; Schizophrenia

Mesh:

Year:  2017        PMID: 28663026     DOI: 10.1016/j.schres.2017.06.032

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

1.  The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.

Authors:  J A Arnaiz; C Rodrigues-Silva; G Mezquida; S Amoretti; M J Cuesta; D Fraguas; A Lobo; A González-Pinto; M C Díaz-Caneja; I Corripio; E Vieta; I Baeza; A Mané; C García-Rizo; M Bioque; J Saiz; M Bernardo; S Mas
Journal:  Psychopharmacology (Berl)       Date:  2020-11-23       Impact factor: 4.530

Review 2.  Stress, Telomeres, and Psychopathology: Toward a Deeper Understanding of a Triad of Early Aging.

Authors:  Elissa S Epel; Aric A Prather
Journal:  Annu Rev Clin Psychol       Date:  2018-03-01       Impact factor: 18.561

3.  Risk factors for metabolic syndrome in individuals with recent-onset psychosis at disease onset and after 1-year follow-up.

Authors:  Yolanda Alonso; Carmen Miralles; M José Algora; Alba Valiente-Pallejà; Vanessa Sánchez-Gistau; Gerard Muntané; Javier Labad; Elisabet Vilella; Lourdes Martorell
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

Review 4.  Obesity in Adolescents with Psychiatric Disorders.

Authors:  Ariana M Chao; Thomas A Wadden; Robert I Berkowitz
Journal:  Curr Psychiatry Rep       Date:  2019-01-19       Impact factor: 5.285

Review 5.  Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia.

Authors:  Tyler R Prestwood; Roshanak Asgariroozbehani; Sally Wu; Sri Mahavir Agarwal; Ryan W Logan; Jacob S Ballon; Margaret K Hahn; Zachary Freyberg
Journal:  Behav Brain Res       Date:  2021-01-14       Impact factor: 3.332

6.  Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis.

Authors:  Maria Fe Barcones; Karina Soledad MacDowell; Borja García-Bueno; Miquel Bioque; Leticia Gutiérrez-Galve; Ana González-Pinto; Maria José Parellada; Julio Bobes; Miguel Bernardo; Antonio Lobo; Juan Carlos Leza
Journal:  Int J Neuropsychopharmacol       Date:  2018-05-01       Impact factor: 5.176

7.  Psychological trauma occurring during adolescence is associated with an increased risk of greater waist circumference in Early Psychosis patients treated with psychotropic medication.

Authors:  Luis Alameda; Axel Levier; Mehdi Gholam-Rezaee; Philippe Golay; Frederik Vandenberghe; Aurélie Delacretaz; Philipp Baumann; Anaïs Glatard; Céline Dubath; Andres Herane-Vives; Victoria Rodriguez; Alessandra Solida; Kim Q Do; Chin B Eap; Philippe Conus
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.240

8.  Metabolic syndrome following a first episode of psychosis: results of a 1-year longitudinal study conducted in metropolitan Lisbon, Portugal.

Authors:  Ricardo Coentre; Pedro Levy; Carlos Góis; Maria Luísa Figueira
Journal:  J Int Med Res       Date:  2022-06       Impact factor: 1.573

9.  Twelve-month outcomes in overweight/obese users with mental disorders following a multi-element treatment including diet, physical activity, and positive thinking: The real-world "An Apple a Day" controlled trial.

Authors:  Laura Giusti; Valeria Bianchini; Annalisa Aggio; Silvia Mammarella; Anna Salza; Stefano Necozione; Alessia Alunno; Claudio Ferri; Massimo Casacchia; Rita Roncone
Journal:  Front Psychiatry       Date:  2022-08-23       Impact factor: 5.435

10.  Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort.

Authors:  Javier Vázquez-Bourgon; Jaqueline Mayoral-van Son; Marcos Gómez-Revuelta; María Juncal-Ruiz; Víctor Ortiz-García de la Foz; Diana Tordesillas-Gutiérrez; Rosa Ayesa-Arriola; Miquel Bioque; Benedicto Crespo-Facorro
Journal:  Int J Neuropsychopharmacol       Date:  2021-01-20       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.